|

New Imaging Biomarkers Predictive of MA Progression

RECRUITINGN/ASponsored by Poitiers University Hospital
Actively Recruiting
PhaseN/A
SponsorPoitiers University Hospital
Started2023-10-02
Est. completion2027-10-02
Eligibility
Age60 Years – 90 Years
Healthy vol.Accepted

Summary

The pathophysiology of AD is complex. In addition to amyloid plaques and neurofibrillary degeneration, there is a metabolic alteration of the energy pathways, oxidative phosphorylation and glycolysis, which are involved in brain function. Several authors have shown a series of early metabolic dysregulations via an increase in phosphorylation at the origin of neuronal death. Ultra-high field imaging (7T MRI) may allow, with its better spatial resolution and advanced imaging techniques, to shed light on the mechanisms of progression of Alzheimer's disease. A Magnetic Resonance Spectroscopy (MRS) examination can be coupled to brain MRI without additional risk for the patient. Multinuclear 1H-31P metabolic imaging is a promising tool that can provide information on the metabolic evolutionary profile of AD. Thus, we propose a longitudinal study in patients with early-stage AD on 7T MRI-MRS.

Eligibility

Age: 60 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* French-speaking patients aged 60 to 90 years,
* Patient in the context of Alzheimer's disease \* for which imaging after MRI is prescribed as part of the usual diagnostic process,

  \*Alzheimer's disease is diagnosed by the doctor of the memory consultation and is defined by :Evidence of a storage disorder in verbal episodic memory at LR/RI defined by a sum of LR \< 17/48 and sum of RT \< 40/48 +/- Impairment of executive functions possible (BREF, TMT grefex, verbal fluencies) +/- Impairment of instrumental functions possible (Grémots noun naming, Rey's figure, Mahieux's Battery).
* MMSE score ≥18,
* Written informed consent after the patient has been informed,
* Progressive decline for at least 6 months.

Exclusion Criteria:

--Partially or completely illiterate patient unable to read and write,

* Patient with an absolute contraindication to 7T MRI
* Severe psychiatric pathology not balanced,
* Non-degenerative neurological disease (stroke, multiple sclerosis ...),
* Patient with tumor or inflammatory pathology, or vascular leukopathy visualized in MRI (Fazekas score \> 3)

Conditions6

Alzheimer DiseaseAlzheimer's DiseaseMR BiomarkersMagnetic Resonance SpectroscopyProgression of DiseaseUltra High Field 7T

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.